Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Primary Indications
* Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Dose can be increased by 5-10 mg every week based on clinical response and tolerability.
* **Maintenance:** Usual effective dose is 10-20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg/day). In some cases, doses up to 30 mg twice daily (60 mg/day) may be considered under strict medical supervision, but efficacy and safety beyond 40 mg/day are not well established.
## Pediatric Dosing (2 years and older)
* **Initiation:** 2.5 mg twice daily.
* **Titration:** Dose can be increased by 2.5-5 mg every week based on clinical response and tolerability.
* **Maintenance:** Usual effective dose is 5-10 mg twice daily.
* **Maximum:** 10 mg twice daily (20 mg/day). Doses up to 20 mg twice daily (40 mg/day) may be considered in larger pediatric patients under strict medical supervision.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Lower doses may be needed.
* **Renal Impairment:** Use with caution. Lower doses may be needed.
* **Concomitant Medications:**
* **Strong CYP3A4 Inhibitors:** May increase clobazam levels; consider reducing clobazam dose.
* **Strong CYP3A4 Inducers:** May decrease clobazam levels; consider increasing clobazam dose.
* **Other CNS Depressants:** Use caution due to additive sedative effects.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, aggression, irritability, constipation, ataxia, fatigue, vomiting.
* **Serious:** Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms (seizures, rebound insomnia, anxiety), suicidal behavior or ideation, respiratory depression, dependence and abuse.
## Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other benzodiazepines, sedatives/hypnotics):** Additive CNS depression, potentially leading to profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** Increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** Decrease clobazam concentrations.
* **Stimulants (e.g., amphetamines):** May reduce the effectiveness of clobazam.
* **UGT2B7 Substrates:** Clobazam is a moderate inhibitor of UGT2B7. Monitor for potential increases in the concentration of co-administered UGT2B7 substrates.
## Monitoring
* **Efficacy:** Monitor seizure frequency and type.
* **Tolerability:** Assess for somnolence, dizziness, cognitive impairment, and behavioral changes.
* **Withdrawal Symptoms:** Monitor for signs of withdrawal upon dose reduction or discontinuation, especially in patients taking higher doses or for prolonged periods.
* **Skin Reactions:** Advise patients to report any new or worsening rash.
* **Suicidal Ideation:** Monitor for changes in behavior and mood, and report any suicidal thoughts or behaviors immediately.
## Clinical Pearls
* Clobazam is generally initiated at a low dose and gradually titrated upwards to minimize adverse effects.
* Rapid discontinuation can precipitate withdrawal symptoms, including seizures. Tapering is recommended.
* Due to the risk of somnolence, patients should be cautioned about operating machinery or driving until they know how the medication affects them.
* Clobazam has a longer half-life than many other benzodiazepines, which may allow for once or twice-daily dosing.
---
***Disclaimer:** This information is intended for clinical use and does not replace the need to consult the official prescribing information and current literature. Always verify drug information with the most current resources before making clinical decisions.*
